(Q44319715)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12592326%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

title

Effect of imatinib on haematopoietic recovery following idarubicin exposure (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12592326%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

Carlo Gambacorti-Passerini

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12592326%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Loredana Cleris

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12592326%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

author name string

Ruchatz H

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12592326%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Puttini M

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12592326%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Pilotti S

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12592326%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Formelli F

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12592326%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

publication date

1 February 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12592326%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12592326%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12592326%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12592326%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

298-304

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12592326%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402800

31 October 2019

exact match

0 references

cites work

Stem cell factor induces proliferation and differentiation of highly enriched murine hematopoietic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

Requirement for mast cell growth factor for primordial germ cell survival in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

Ultrastructural identification of the c-kit-expressing interstitial cells in the rat stomach: a comparison of control and Ws/Ws mutant rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice--evidence for an impaired c-kit kinase in mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

Role of kit-ligand in proliferation and suppression of apoptosis in mast cells: basis for radiosensitivity of white spotting and steel mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

Activating c-kit gene mutations in human germ cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

Basis of hematopoietic defects in platelet-derived growth factor (PDGF)-B and PDGF beta-receptor null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

In VivoDifferentiation of Mast Cells from Acute Myeloid Leukemia Blasts Carrying a Novel Activating Ligand-Independent C-kit Mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

7 January 2021

Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

7 January 2021

Oral idarubicin in patients with late chronic phase chronic myelogenous leukemia or chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

7 January 2021

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

7 January 2021

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402800

7 January 2021